FDA approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the front of the eye).
Read more: FDA approves first drug for neurotrophic keratitis, a rare eye disease